Skip to main content
Dx & Vx Co., Ltd. logo

Dx & Vx Co., Ltd. — Investor Relations & Filings

Ticker · 180400 ISIN · KR7180400004 KO Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2021-08-27 Capital/Financing Update
Country KR South Korea
Listing KO 180400

About Dx & Vx Co., Ltd.

https://www.dxvx.com/

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). This document outlines the issuance of new shares, the purpose of capital raising, the third-party allocation details, and the impact on shareholding structure. This falls under the category of capital and financing updates.
2021-08-27 Korean
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the decision to acquire shares of another corporation (타법인 주식 및 출자증권 양수결정). It details the acquisition of shares in Hanmi Science Co., Ltd. by Cancerrop, including valuation methods, board resolution details, and financial summaries of the target company. This falls under the category of corporate regulatory filings related to capital structure and investment activities, which is best classified as a Regulatory Filing (RNS) as it is a specific disclosure of a material corporate event.
2021-08-27 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'CancerRop' covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial information, business descriptions, and management reports, which fits the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-17 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the company 'CancerRop' (주)캔서롭, covering the fiscal period from January 1, 2020, to December 31, 2020. It contains detailed financial information, business descriptions, governance details, and management disclosures. Although it includes a 'Correction Report' (정정신고) header at the beginning, the document itself is the full annual business report (10-K equivalent in the Korean market). FY 2020
2021-06-10 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company CancerRop (주)캔서롭, covering the period from 2021.01.01 to 2021.03.31. It contains detailed financial information, company overview, capital changes, and management details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-17 Korean
기타시장안내(기업심사위원회 속개 결정 안내)
Legal Proceedings Report Classification · 100% confidence The document is a short announcement (260 characters) from the stock exchange regarding a 'Corporate Review Committee' decision to continue deliberations on the company's listing status. It does not contain full financial statements or legal filings, but rather serves as a regulatory notification regarding market status. As it does not fit into specific categories like M&A or dividends, it falls under the general regulatory announcement category.
2021-04-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.